1

Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off 

What a difference a year makes. Last year at this time we were heading into wave something or other of COVID, lockdowns and travel restrictions were still in place and people everywhere were getting pretty sick and tired of the whole situation. In Canada, we had the added reminder of massive protests in Ottawa and various border crossings. Life in general was not straightforward, nor was it ideal for the average individual. One year later, that seems like a distant memory and life is pretty much back to normal as long as you don’t spend too much time following global politics.

You may be wondering why I’m doing this look back? Because almost exactly one year ago was the last time I had a look at today’s company.

Not only has the world changed considerably in the last 12 months, so has Valeo Pharma Inc. (TSX: VPH | OTCQB: VPHIF). Valeo Pharma is a fast growing pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory/Allergy, Ophthalmology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the necessary capabilities and a complete infrastructure to register and manage its growing product portfolio through all stages of commercialization.

On Monday, Valeo released it’s Fiscal 2022 results (for the year ended October 31, 2022) that included some pretty impressive growth in revenue and adjusted gross profit. But before we dig into the numbers here are a few key highlights from the last 12 months:

  • In March 2022, the Company received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange (“TSX”) with an effective trading date of March 29, 2022;
  • In July 2022, the Company entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two innovative ophthalmic therapies, XIIDRA® and SIMBRINZA® in Canada;
  • In July 2022, the Company entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for the Canadian rights to ALLERJECT, (epinephrine injection, USP) auto-injector for the treatment of serious allergic reactions;
  • In July 2022, the Company closed a non-dilutive US$30 million Secured Term Loan from Sagard Healthcare Partners;
  • In August 2022, the Company appointed Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer and Jean-François Fournier as its new Business Unit Head – Ophthalmology;
  • In September 2022, the Company entered into a Commercial Services Agreement with Veru Inc. for sabizabulin in Canada, a novel dual antiviral and anti-inflammatory agent being targeted for the treatment of hospitalized moderate-severe COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and death

Adding numerous commercial assets to Valeo’s product portfolio had a material impact on the top line as the Company posted record 2022 revenues of C$27.7 million for the year-ended October 31, 2022 compared to C$13.6 million for the year-ended October 31, 2021 for a 105% increase. Record adjusted gross profit was C$9.4 million for the year-ended October 31, 2022 compared to C$4.5 million for the year-ended October 31, 2021, representing a 109% increase. A lot of this growth came in the Company’s fiscal Q4 where record revenues were C$12.7 million for the quarter ended October 31, 2022 compared to C$3.4 million for the quarter ended October 31, 2021 representing a 274% increase. The investments Valeo has made during prior years in its corporate and commercial infrastructure is starting to pay off by providing considerable operating leverage which is fueling this growth and paving a path towards profitability.

Valeo now has a total of 14 treatments/therapies in its product portfolio which has the Company anticipating that all its business units will continue to produce strong revenue and margin growth in 2023 as it forecasts delivering record quarterly revenues again in the first quarter of 2023. Annualized revenue run-rate as at the end of FY-22 now exceeds C$50 million, which represents a significant increase over the FY-22 record revenues of C$27.9 million.

Over the last year, it appears Valeo Pharma has really hit its stride. As long as the Company can keep growing its top line without continuing to add to the 115 full-time employees, that revenue should start to filter down to the bottom line and make investors happy. With a market cap of C$50 million, Valeo is currently trading at 1x its annualized revenue run rate.




Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue

In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and Director Steve Saviuk about Valeoi’s record Q3 revenue and the addition of three new therapeutic drugs to its portfolio.

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Steve discusses Valeo’s acquisition of two opthalmic therapies from Novartis Pharmaceuticals under a commericalization agreement, as well as a new license with Kaleo Inc. for an auto-injector for serious allergic reactions. These three additional Health Canada approved products, Steve says, “are accretive immediately to us. The three products had existing revenues of $27 million, and we expect that to grow so our total revenue base basically doubled on the day that we made that acquisition.”

Steve also discusses Valeo’s record Q3 revenues of $6.1 million from sales ($15.1 million YTD), and Valeo’s cash position of over $27 million. Steve says that “those are trends that we expect to see continue.” He also says that with the recent hiring of former Novartis VP Kyle Steiger as Senior VP of Valeo, and the expansion of its sales team to 80-85 people, Valeo is poised for rapid commercial and revenue growth.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].




Valeo Pharma’s Steve Saviuk talks about the US$40M non-dilutive financing from Sagard Healthcare Partners

In this InvestorIntel interview with host Tracy Weslosky, Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and Director Steve Saviuk talks about closing a US$40 million non-dilutive financing from Sagard Healthcare Partners and explains why Valeo is at “the right place at the right time with the right products.”

In the interview, which can also be viewed in full on the InvestorIntel YouTube channel (click here to access InvestorChannel.com), Steve says that the proceeds from the financing will be utilized to fund acquisition of Canadian rights to 3 growing commercial stage drugs which will “more than double our current revenue run rate.” Providing an update on Valeo’s licensing agreement with Kaléo for the Canadian rights to ALLERJECT® he says, “We are relaunching it. Sales were $4 million last year we expect sales to grow to about $25 million.” Steve also talks about adding ophthalmology as a new therapeutic focus for Valeo with the acquisition of the Canadian license rights to two innovative ophthalmic therapies from Novartis.

To access the full InvestorIntel interview, click here

Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.

About Valeo Pharma

Valeo Pharma is a pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respirology/Allergy, Ophthalmology and Specialty Products. Headquartered in Kirkland, Quebec, Valeo Pharma has the full capability and complete infrastructure to register and properly manage its growing product portfolio through all stages of commercialization.

To know more about Valeo Pharma Inc., click here

Disclaimer: Valeo Pharma Inc. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].